Maternal SARS-CoV-2 infection during pregnancy raises questions that extend beyond the mother’s symptoms. The placenta supplies oxygen and nutrients, regulates hormones and forms a selective barrier between maternal and fetal circulation. It can also become infected or injured. Separating the effects of viral placental infection, maternal inflammation, impaired placental blood flow and prematurity is essential for interpreting pathology and neonatal outcomes.
The planned 21st Congress of the Federation of Asian and Oceania Perinatal Societies in Tokyo was cancelled in April 2020 as international travel became dangerous. Its scientific programme had addressed perinatal medicine, maternal health and neonatal research. The experience reinforced the need for coordinated pathology, reliable surveillance and follow-up of children exposed to infection before birth.
SARS-CoV-2 enters susceptible cells through receptors including ACE2 and TMPRSS2. Their expression in the placenta varies by gestational age, placental region and cell type, so susceptibility cannot be inferred from receptor findings alone. Researchers have demonstrated viral RNA or antigen in placental tissue in some pregnancies, while many placentas remain unaffected. Detection in the placenta also does not establish that the virus reached the fetus.
Pathologists assess both infection and its consequences. Findings associated with SARS-CoV-2 placentitis include syncytiotrophoblast necrosis, chronic histiocytic intervillositis, perivillous fibrin deposition and inflammation within chorionic vessels. These patterns are not present in every infected placenta, and several can occur with other conditions. Clinical history, maternal testing, placental examination and neonatal results must therefore be interpreted together.
The timing of maternal infection may influence the observed pattern. Infections early in pregnancy have coincided with fetal growth restriction, miscarriage, stillbirth and preterm birth, while later infections have more often been associated with acute placental inflammation. These observations come largely from case series and retrospective cohorts, where differences in testing, disease severity and underlying pregnancy risk complicate direct comparison.
Placental injury is rarely attributable to a single cause. Maternal vascular malperfusion can result from preeclampsia, thrombophilia, diabetes or hypoxaemia. Chronic villitis and intervillositis may reflect immune, infectious or unidentified processes. SARS-CoV-2 infection can coexist with these conditions. A placenta positive for the virus should not be treated as proof that viral infection caused every abnormality seen in the infant.
Maternal infection may affect pregnancy through systemic inflammation, endothelial injury, coagulability changes and reduced oxygen delivery. Severe COVID-19 has been associated with hypertensive disorders, thrombotic complications, fetal growth restriction and increased neonatal care requirements. The size of these associations has varied between studies, and illness severity, gestational timing and pre-existing conditions remain important confounders.
The broad perinatal research agenda preserved in the FAOPS 2020 congress programme remains a sound basis for examining these pathways. Useful studies combine placental examination with maternal blood tests, cord blood findings and neonatal microbiology. Standardised sampling times and definitions help distinguish infection acquired before birth from postnatal exposure. For international specimen exchange, customs and biosecurity requirements can affect chain of custody, making careful documentation essential without delaying clinical care.
Antenatal transmission is biologically possible but uncommon. Most newborns with confirmed SARS-CoV-2 infection have had a parent with active infection around delivery, and some acquired the virus after birth through close contact. Placental viral detection raises the possibility of transmission but cannot determine the route or timing of infection on its own. Maternal and neonatal testing should be guided by the clinical situation and current public-health guidance.
Prematurity remains the major pathway connecting maternal infection with neonatal morbidity. Some studies have reported increased rates of preterm birth, stillbirth and neonatal intensive care admission, while many infected newborns have remained well or developed mild respiratory illness. Feeding difficulties, temperature instability and separation from the mother may add to the care burden without indicating severe fetal disease. Follow-up should be based on the infant’s condition, gestational age and documented exposure rather than a positive placental result alone.
Australia’s Medicare-funded public maternity services, midwives, general practitioners and obstetric specialists provide a framework for coordinated care. Tertiary placental pathology and neonatal intensive care resources are concentrated in major cities including Melbourne, Sydney, Brisbane, Perth and Adelaide. Regional families may rely on telehealth, shared-care arrangements and transfer pathways, making the availability of transport and timely pathology review important parts of rural care.
Aboriginal and Torres Strait Islander families should receive culturally safe, coordinated care through Aboriginal medical services, maternal child health teams and community-controlled maternity services where available. Pandemic-era border closures, flight limits and hotel quarantine also affected how families travelled and how staff attended deliveries. Current state and federal advice should be checked directly, as quarantine and testing requirements have changed over time. International collaboration and specimen transfer must also meet Australian Border Force, customs and biosecurity obligations.
The archived discussion of maternal nutrition and microbiomes highlights how maternal diet, antibiotics, mode of birth and gestational age may influence the infant’s early microbial community. Infection and its treatment can add further biological changes. At present, there is no evidence that a special diet or supplement clears SARS-CoV-2 from the placenta or prevents transmission.
The Australian market offers many folic acid and iodine supplements through pharmacies and supermarkets, along with products containing vitamin D and other nutrients. The Therapeutic Goods Administration regulates listed medicines and supplements, but nutrient concentrations still differ between brands. Pregnancy multivitamins commonly contain around 400 micrograms of folic acid, while iodine content varies. High-dose vitamin A can cause fetal harm, so additional supplements should be discussed with a maternity clinician rather than combined independently.
Placental inflammation may provide useful information about fetal development, but evidence remains insufficient to recommend routine neurological or developmental screening solely because a placenta tested positive. Growth, feeding, hearing and developmental reviews should follow usual clinical indications and be tailored to each child. Families may also value practical guidance on nutrition, safe feeding and emotional wellbeing after a pregnancy affected by infection.
Better evidence depends on linking placental pathology with maternal, cord and neonatal samples while recording the stage of pregnancy and the timing of tests. International registries can help distinguish the effects of infection from prematurity, placental insufficiency and pre-existing disease. Longer follow-up may reveal subtle differences in growth or development, but outcomes should not be assumed and should not be used to create unnecessary anxiety.
Placental results can be difficult to explain because a positive test may represent infection without fetal transmission or injury. Clear counselling should distinguish what was observed, what remains uncertain and which follow-up is recommended. Broader child and family support can be explored through organisations such as Jump for the Children, alongside local health services, women’s centres and family networks.
| Pathological pattern | Characteristic findings | Possible clinical associations | Important limitation |
|---|---|---|---|
| SARS-CoV-2 placentitis | Syncytiotrophoblast necrosis, histiocytic intervillositis and perivillous fibrin | Maternal infection, preterm birth, growth restriction and fetal compromise | Findings are not specific to SARS-CoV-2 and require clinical correlation |
| Maternal vascular malperfusion | Infarction, villous agglutination and reduced terminal villous development | Preeclampsia, fetal growth restriction and chronic placental hypoxia | Can accompany infection without proving a viral cause |
| Fetal inflammatory response | Chorionic vasculitis, funisitis and increased fetal inflammatory cells | Possible fetal infection, sepsis and neonatal illness | Inflammatory changes are nonspecific and need microbiological assessment |
| No specific placental abnormality | Routine or age-related findings without a characteristic injury pattern | Outcomes may still be influenced by prematurity or postnatal exposure | A negative placenta does not exclude maternal or neonatal infection |
Clinicians and families can turn current evidence into better care by documenting maternal and neonatal testing, retaining placental tissue when pathology is indicated, discussing feeding and newborn-care plans, and arranging follow-up according to the infant’s clinical condition. Sharing de-identified findings with appropriate research networks will help identify the pathways associated with preventable harm. Every pregnancy affected by SARS-CoV-2 deserves coordinated care, clear communication and an individualised plan for the baby’s health.